Tyra Biosciences, Inc. (TYRA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 126.32M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 33.28M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -160.46M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $126.32M | (m) | $33.28M | $-160.46M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $111.43M | (m) | $29.43M | $-142.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $102.93M | (m) | $28.01M | $-132.76M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $96.92M | (m) | $27.08M | $-125.99M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $94.15M | (m) | $27.08M | $-121.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $87.84M | (m) | $25.11M | $-113.70M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $80.08M | (m) | $22.80M | $-104.18M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $78.57M | (m) | $20.29M | $-100.07M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $75.15M | (m) | $17.09M | $-95.45M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $69.31M | (m) | $15.21M | $-87.93M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $62.52M | (m) | $13.53M | $-79.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $52.24M | (m) | $12.25M | $-69.33M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $43.89M | (m) | $8.89M | $-59.01M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $43.77M | (m) | $9.05M | $-58.43M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $43.01M | (m) | $10.59M | $-58.93M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $39.86M | (m) | $9.55M | $-53.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $34.43M | (m) | $9.04M | $-46.83M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $26.76M | (m) | $6.68M | $-36.91M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $20.64M | (m) | $2.89M | $-26.29M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $7.20M | (m) | $439.00K | $-9.30M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |